Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Retifanlimab (anti-PD-1) - Primary antibody, specific to PDCD1, >95%, high purity, Human IgG4SP, Antibody of programmed cell death 1 (CD279)

Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG4SP
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175644
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175644-100μg
100μg
In stock
$59.90
Ab175644-1mg
1mg
In stock
$279.90
Ab175644-5mg
5mg
In stock
$739.90
Ab175644-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,189.90
Add to Wish List Compare
Bulk Order  DATASHEET

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Click to view target information: PDCD1
Accession#:Q15116 Gene ID:5133 PD1 PDCD1 programmed cell death 1 (CD279) Antibody

Basic Description

Product NameRetifanlimab (anti-PD-1) - Primary antibody, specific to PDCD1, >95%, high purity, Human IgG4SP
SynonymsCD279 antibody | CD279 antigen antibody | hPD 1 antibody | hPD l antibody | hPD-1 antibody | hSLE1 antibody | PD 1 antibody | PD-1 antibody | PD1 antibody | PDCD 1 antibody | PDCD1 antibody | PDCD1_HUMAN antibody | Programmed cell death 1 antibody | Progr
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityPDCD1
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeANTAGONIST
Mechanism of actionAntibody of programmed cell death 1 (CD279)
Product Description

Retifanlimab (anti-PD-1) is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab (anti-PD-1) can be used for the research of gastroesophageal adenocarcinoma (GEA).

Product Properties

IsotypeHuman IgG4SP
Light Chain Typekappa
SDS-PAGE25.5 kDa (Light Chain) & 50.1kDa (Heavy Chain), under reducing conditions; 179.1 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS2079108-44-2

Images

Retifanlimab (anti-PD-1) (Ab175644) - Flow Cytometry
Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated MOLT-4 cells (24h) labelling PD-1 (red) with Retifanlimab (anti-PD-1) (Ab175644). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.


Retifanlimab (anti-PD-1) (Ab175644) - ELISA
Immobilized hu-PD-1 at 2 μg/mL can bind Retifanlimab (anti-PD-1) (Ab175644) with the EC₅₀ of 55.56 ng/mL.

Retifanlimab (anti-PD-1) (Ab175644) - SEC
The purity of Retifanlimab (anti-PD-1) (Ab175644) is more than 95% verified by HPLC.

Retifanlimab (anti-PD-1) (Ab175644) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Retifanlimab (anti-PD-1) (Ab175644) with the EC50 of 11.39 ng/mL.

Associated Targets(Human)

PDCD1 Tclin Programmed cell death protein 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDCD1 Tclin Programmed cell death protein 1 (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDCD1 Tclin Programmed cell death protein 1/Programmed cell death 1 ligand 1 (1367 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0303705Certificate of AnalysisMar 26, 2024 Ab175644
ZJ24F0303704Certificate of AnalysisMar 26, 2024 Ab175644
ZJ24F0303703Certificate of AnalysisMar 26, 2024 Ab175644

Related Documents

 SDS

 Specification Sheet

References

1. Farias JPF, Rangel da Silva MHC, Jácome AA.  (2021)  Emerging and Experimental Agents for Anal Cancer: What is New?.  J Exp Pharmacol,  13  (3): (433-440).  [PMID:33859504]
2. Kline J, Gajewski TF.  (2010)  Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer..  Curr Opin Investig Drugs,  11  (12): (1354-9).  [PMID:21154117]
3. Hall RD, Gray JE, Chiappori AA.  (2013)  Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer..  Cancer Control,  20  (1): (22-31).  [PMID:23302904]
4. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al..  (2017)  Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice..  Mol Cancer Ther,  16  (5): (861-870).  [PMID:28265006]
5. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips.  (1997-10-23)  The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors..  Gene,  197  ((1-2)): (177-187).  [PMID:9332365]
6. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T..  (1994)  Structure and chromosomal localization of the human PD-1 gene (PDCD1)..  Genomics,      [PMID:7851902]
7. Prokunina, Ludmila L and 23 more authors..  (2002)  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans..  Nature genetics,      [PMID:12402038]
8. Topalian, Suzanne L SL and 29 more authors..  (2012)  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer..  The New England journal of medicine,    (28):   [PMID:22658127]
9. Robert, Caroline C and 27 more authors..  (2015)  Nivolumab in previously untreated melanoma without BRAF mutation..  The New England journal of medicine,    (22):   [PMID:25399552]
10. McDermott, J J and Jimeno, A A..  (2015)  Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer..  Drugs of today (Barcelona, Spain : 1998),      [PMID:25685857]
11. Na, Zhenkun and 6 more authors..  (2017)  Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab..  Cell research,      [PMID:27325296]
12. Pascolutti, Roberta R and 6 more authors..  (2016)  Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant..  Structure (London, England : 1993),    (4):   [PMID:27618663]
13. Horita, Shoichiro S and 5 more authors..  (2016)  High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1..  Scientific reports,    (13):   [PMID:27734966]
14. Tan, Shuguang S and 15 more authors..  (2017)  An unexpected N-terminal loop in PD-1 dominates binding by nivolumab..  Nature communications,    (6):   [PMID:28165004]
15. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ..  (2018)  PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene..  Gene,    (5):   [PMID:28951311]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.